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Epidemiology and Risk Factors
General epidemiology
Human T cell lymphotrophic virus 1 (HTLV)-1 is a delta
retrovirus endemic in the Caribbean, parts of South Amer-
ica (highest rates reported in Brazil, Peru, Ecuador and
Venezuela), West Africa, Asia (particularly Southwestern
Japan) and Oceania. In areas of highest endemicity, 2–6%
of adults are infected (1,2). Infection is much less common
in North America. For example, in the United States (US)
0.035–0.046% of blood donors are infected with HTLV-1
or HTLV-2 (3). Among potential organ donors in France
and the United States, similarly low rates of HTLV-1 (0.03–
0.067%) have been reported (4,5). In endemic areas,
breastfeeding is the predominant mode of transmis-
sion (2). HTLV-1 may also be transmitted via intravenous
drug use, sexual intercourse (inefficiently), solid organ
transplantation (SOT) and transfusion of cell-containing
blood products (14.4–47.3% of recipients) (6,7). HTLV-2,
in contrast, is primarily found in intravenous drug users
and sexual contacts of infected persons and is endemic in
some indigenous populations of North, Central and South
America and in West and Central Africa.
HTLV-1 establishes latent infection in lymphocytes and in-
fection persists for life. While most patients remain asymp-
tomatic, following a prolonged period of latency 2–5% of
infected patients develop adult T cell leukemia/lymphoma
(ATL). In Southwestern Japan, 75% of non-Hodgkins lym-
phoma (NHL) is ATL (7). In addition to ATL, a small per-
centage of infected individuals develop severe neurological
disease termed HTLV-1 associated myelopathy/tropical
spastic paraparesis (HAM/TSP). Other inflammatory disor-
ders and less severe neurological disease have also been
associated with HTLV-1 and no reliably effective treatment
is available. Unlike HTLV-1, the link between HTLV-2 and hu-
man disease is uncertain, although there have been occa-
sional case reports of neurological disease, inflammatory
disorders, and leukemia in infected patients (8). Thus at
present, for the purpose of organ donation, HTLV-2 is not
considered a human pathogen and organs from HTLV-2
positive donors are generally not considered to present
an increased risk of donor-derived disease compared to
organs from HTLV-2 negative donors. This guideline will
focus on HTLV-1 infection.
Recipients positive pretransplantation
The effect of immunosuppression on the natural history of
HTLV-1 is not well defined as very few cases have been
described. This is an important issue in determining the
safety of organ transplantation in HTLV-1 positive recip-
ients. Case series from Japan describe 35 HTLV-1 posi-
tive kidney recipients with long-term follow up; no HTLV-1
disease occurred (9–11). In contrast, a series of patients
with posttransplant lymphoproliferative disease (PTLD) de-
scribes the development of HTLV-1 associated ATL in five
renal transplant recipients (unknown if all cases were in-
fected pre-transplant) with death occurring in four or five
patients (12). Among 26 HTLV-1 positive living donor liver
recipients, four (15%) developed ATL with fatal outcomes
in all cases (13). Overall survival, however, did not differ
between HTLV-1 positive and negative recipients.
Donor derived HTLV-1 infection
Since 1999, 162 HTLV 1/2 screen positive organs have
been transplanted in the United States with no HTLV-1
associated disease described in recipients (5,14,15). In vir-
tually all cases, however, confirmatory tests were not per-
formed on donors and analysis based on the performance
of the HTLV-1/2 screening assay in a low seroprevalence
population indicates that most of these donors had HTLV-2
or a false positive screening assay (5). Further, the OPTN
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database tracks malignancy but not neurological outcome.
Thus, the absence of reports of HTLV-1 associated disease
in this population does not indicate that true positive HTLV-
1 organs can be safely transplanted.
Only a few case reports describe proven HTLV-1 trans-
mission from seropositive donor to seronegative recipient
(16–19). The most convincing case of donor-derived dis-
ease occurred in Spain in which three seronegative recipi-
ents of an HTLV-1 seropositive donor developed myelopa-
thy within 2 years of transplantation (17). A heart transplant
who received HTLV-1 infected blood at the time of trans-
plantation developed severe HAM 18 weeks after trans-
plantation (20). A number of other reports describe donor
to recipient HTLV-1 transmission without known develop-
ment of disease (13,16,18,19).
Recommendation: While the impact of immunosuppres-
sion on the natural history of HTLV-1 is not fully under-
stood, persons seropositive for HTLV-1 can be considered
for transplantation. Given that these recipients may face a
higher (but difficult to quantify) risk of serious disease (ATL
and HAM/TSP), information regarding this risk should be
provided to HTLV-1 positive potential recipients as part of
the informed consent process (Category II-2).
Diagnosis
Laboratory diagnosis of HTLV-1
Enzyme linked immunosorbent assays (EIA) are currently
used as screening tests for HTLV-1/2. These tests do not
distinguish between HTLV-1 and HTLV-2. Further, diagno-
sis of HTLV-1 infection is a two-step process requiring a
confirmatory assay. The most commonly used confirma-
tory assays include Western blot and line immunoassays.
Depending on the assay design and the results in a partic-
ular patient, these confirmatory immunoassays may distin-
guish between HTLV-1 and HTLV-2. Polymerase chain re-
action (PCR) tests may also be useful to confirm infection
(particularly in the case of an indeterminate confirmatory
test) and can distinguish between infection with HTLV-1
and HTLV-2. As plasma viremia is not prominent in HTLV-
1 infection, PCR tests are best performed on peripheral
blood mononuclear cells (PBMCs). In some studies, how-
ever, PCR is less sensitive than serological methods for the
diagnosis of HTLV-1/2, and may be even lower for HTLV-2
(21). No confirmatory tests or nucleic acid based tests are
currently approved by the FDA, and in most settings confir-
matory results are not available in a time frame adequate to
make decisions regarding deceased donor organ donation.
Screening EIA tests are highly sensitive but have poor pos-
itive predictive value when applied to a low seroprevalence
population. For example, using the Abbott HTLV I/II EIA as-
say (now discontinued) 15 215 blood donors, 51 (0.35%)
were repeatedly reactive; only 10 of these had positive
confirmatory tests and only 4 had confirmed HTLV-1. Thus,
only 4/51 (7.9%) of screen positive patients had confirmed
HTLV-1 infection (22). In patients with medical conditions
unrelated to HTLV-1/2, higher rates of positive screens
are obtained (26/639), but only 3/26 were confirmed to
have HTLV-1 infection (22). Likewise, among potential or-
gan donors, HTLV-1 infection could not be confirmed in the
majority of screen positive donors (5).
Recommendations: Whenever possible, HTLV-1/2
screen positive results should be confirmed with Western
blot, line immunoassay, or polymerase chain reaction
(Category II-1).
Treatment
Currently no proven medical treatment for asymptomatic
carriers of HTLV-1 exists. Antiretrovirals effective in HIV
infection have achieved mixed results at best in reduc-
ing HTLV proviral loads (the typically stable amount of
virus present in infected cells) (23–27) and this is unsur-
prising as viral replication is sustained by cellular division
rather than highly active viral production (24). Other pro-
posed treatments for asymptomatic carriers or patients
with HAM/TSP include corticosteroids, alpha interferon,
anti-CD25 monoclonal antibody, cyclosporine and valproic
acid which increases viral expression theoretically lead-
ing to enhanced immune surveillance (24). Overall, treat-
ment is focused on management of sequelae of HTLV-
1 infection—namely ATL and HAM/TSP—in carriers who
develop HTLV-1 associated disease.
Recommendations: No specific proven treatment for
asymptomatic HTLV-1 infection is currently available.
Prevention
Donor screening
As a result of both the impending discontinuation of the Ab-
bott HTLV I/II assay in 2009 and concern regarding the high
false positive rate of available assays, an analysis of univer-
sal HTLV-1 screening in deceased donors was undertaken.
This suggested that 167–227 uninfected organs were dis-
carded yearly due to false positive screening tests (5). A
separate analysis estimated that in a low prevalence pop-
ulation the ratio of false positive to true positive HTLV-1
screening assays was 40:1 (28). Based on these consider-
ations, the requirement for HTLV-1 screening of deceased
donors was removed by OPTN/UNOS in 2009.
In general, OPTN/UNOS policy limits recommendations for
laboratory testing to assays approved by the FDA for pur-
pose of donor screening. Currently, three assays are FDA
approved for screening in the United States (29). The char-
acteristics of each assay are described in Table 1. A major
limitation to donor screening is the inability of any licensed
screening test to distinguish HTLV-1 from HTLV-2 and the
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Table 1: FDA approved HTLV-1/2 screening assays
Assay Comments
Abbott HTLV-I/II Practical for OPO use
No longer available in the United States




Designed for large scale use (blood produce
donor screening)
Not practical in most OPO laboratories
Requires significant investment in
expensive equipment and reagents





Approved for HTLV screening
Recently approved (March 2012) and
practicality for OPO use unproven
Does not distinguish between HTLV-1 and
HTLV-2
HTLV = human T cell lymphotrophic virus; OPO = organ
procurement organizations.
lack of a confirmatory test that can be completed prior to
organ donation.
Follow up of recipients at risk for donor-derived
HTLV-1
The optimal management and follow up of recipients re-
ceiving organs from donors proven or suspected to have
HTLV-1 is unknown. In cases of screen positive donors,
every effort should be made to perform confirmatory tests
on stored donor samples to determine if the donor is actu-
ally HTLV-1 infected. Recipients of HTLV-2 positive donors
or those with negative confirmatory assays do not require
specific follow-up. If the donor is proven to have HTLV-1 or
confirmatory tests cannot be done or are indeterminate,
periodic testing for HTLV-1 using both serological (may
have low sensitivity in immunosuppressed patients) and
nucleic acid based testing on the recipient is indicated.
Testing quarterly for 1 year and then biannually for 1 year
would be a reasonable approach. While therapeutic options
are uncertain, recipients would benefit from knowing their
HTLV-1 status to prevent secondary (sexual or breastfeed-
ing) transmission (see later). Further, HTLV-1 viral loads are
higher in patients with neurological disease than in asymp-
tomatic carriers (30,31) and patients with donor-derived in-
fection might benefit from viral load guided modulation in
their immunosuppression. While HTLV-1 viral loads appear
to be maintained by cell division rather than production of
new virus and tend to remain stable, this may not be true
in immunosuppressed patients.
Standardized clinical monitoring for complications of
HTLV-1 infection is not well established. ATL may present
with any of a number of clinical features, including gen-
eralized adenopathy, cutaneous lesions, hypercalcemia,
bony lesions and/or isolated peripheral blood abnormali-
ties/leukemia. HAM/TSP is equally variable in clinical man-
ifestation, and may present with stiff gait, spasticity and
lower extremity weakness, back pain, urinary inconti-
nence, impotence, paresthesias, decreased sensation (par-
ticularly for posterior column modalities such as vibratory
sense) and upper motor neuron signs (32) .
Risk to Staff
HTLV-1 is spread by cell-associated virus, rather than by
cell-free virus and body fluids, and is transmitted by blood
products, sexual activity and breastfeeding. As with other
blood borne pathogens, the greatest risk for healthcare
workers caring for an HTLV-1 infected patient is accidental
inoculation via contaminated sharps. While transmission of
both HTLV-1 and HTLV-2 in the occupational setting have
been reported (33,34), in another report no seroconver-
sions occurred among 34 healthcare workers exposed by
puncture wounds (35). No data exist on appropriate pro-
phylaxis for individuals exposed to HTLV. While some have
recommended the use of antiretroviral agents in settings
of severe exposure (e.g. zidovudine/lamivudine/raltegravir;
Refs. (27,36,37), the CDC and other US agencies do not
recommend postexposure prophylaxis due to the lack
of available data. As with other blood borne pathogens,
universal, standard precautions and scrupulous sharps
safety are considered sufficient for the prevention of HTLV
acquisition.
Risk to others (secondary transmission)
In the nonoccupational setting, transmission may occur
horizontally (usually through sexual activity, or through shar-
ing of injection drug needles) or vertically (mother-to-child,
almost entirely through breastfeeding). These can be is-
sues for a recipient who received an HTLV-1 infected or
possibly infected organ, or for an HTLV-uninfected SOT re-
cipient who may be entering a sexual relationship with
an HTLV-infected partner. The effects of immunosuppres-
sion on the risk of acquisition of HTLV are not under-
stood, though at least one animal model suggests that
cyclosporine at the time of HTLV-1 infection increased
the viral set point and might result in increased risk of
the development of HTLV-1 associated disease (38). For
the HTLV-1 infected SOT recipient, a few general com-
ments apply with respect to transmission. Sexual trans-
mission of HTLV-1 can be prevented effectively with con-
dom use and other safer sex practices (as recommended
for prevention of HIV transmission). Transmission by (in-
jection) needles can be minimized by employment of ster-
ile needles with each use, and by avoidance of sharing
of needles and other potentially contaminated equipment.
Vertical transmission can be decreased by avoidance of
breastfeeding (particularly in the United States and other
resource-rich settings, where breast milk alternatives are
available).
Recommendations: (Table 2)
(1) In low seroprevalence areas (like North America), only
in extreme circumstances should confirmed HTLV-1
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Table 2: Summary of recommendations
Level of
Recommendation evidence Comment
Epidemiology HTLV-1 seropositive individuals should not
be excluded from transplantation, but
informed consent should be obtained.
II-2 Reports demonstrate good outcomes without the
development of HTLV-1 disease after
transplantation.
Immunosuppression may speed the development of
HTLV-1 disease; HTLV-1 related deaths have been
reported after organ transplantation.
Diagnosis Whenever possible, screen positive results
should be confirmed with Western blot,
line immunoassay, or PCR.
III Most screen positive donors or recipients will not
have HTLV-1.
Treatment No specific proven treatment of
asymptomatic HTLV-1 infection is
available.
III Proposed treatments include corticosteroids, alpha
interferon, anti-CD25 monoclonal antibody,
cyclosporine and valproic acid.
Prevention In low seroprevalence areas, confirmed
HTLV-1 positive donors should only be
used in extreme circumstances.
II-3 While routine screening is no longer required, in some
circumstances (e.g. living donors) confirmed
serostatus may be available.
Donor
screening
Routine screening of all deceased donors
for HTLV-1 is not recommended.
III In low seroprevalence areas, most screen positive
donors do not have HTLV-1 resulting in significant
wastage of uninfected organs.
Individual OPO’s with higher prevalence
populations (e.g. immigrants from high
prevalence countries) could consider
targeted screening.
III While a positive screening test in a higher risk donor
is more likely to represent a true positive, even in
this circumstance if a timely confirmatory test
cannot be performed most screen positive donors
will likely not have HTLV-1.
Living donors with epidemiological risk
factors (e.g. previous residence in
endemic area) should be screened as
time frame allows for performance of
confirmatory testing.
III Reports of donor derived HTLV-1 disease justify
testing in higher epidemiological risk donors when
adequate time for confirmatory testing is available.
Recipient
issues
Periodic testing (quarterly for 1 year and
then biannually for 1 year) with both PCR
and serology should be performed on
recipients of proven or suspected HTLV-1
infected donors.
III While no proven intervention is available, recipients
with the potential for donor-derived HTLV-1 should
be made aware of the risk of secondary
transmission (sexual or breastfeeding) and
investigational treatments/prophylaxis could be
considered.
Follow up of HTLV-1 positive SOT recipients
should include regular clinical monitoring
for complications of infection, including
ATL and HAM/TSP.
III Investigational (HAM/TSP) and standard (ATL)
treatments could be considered.
SOT recipients who are HTLV-1 infected (or
received potentially infected organs)
should be counseled about risks of
transmission to others, including how to
minimize those risks.
III HTLV-1 can be transmitted through sexual contact,
breastfeeding, or sharing injection needles. HTLV-1
cannot be transmitted through casual contact.
SOT recipients who are at risk for acquiring
HTLV-1 should be counseled on modes of
transmission and how to minimize the
risk of acquisition. In general, these
recommendations follow those for other
viruses such at HIV or hepatitis C
(Category III).
III This would primarily apply to transplant recipients who
are sexual partners of HTLV-1 infected individuals.
Infection
control
Standard, universal precautions should be
employed when providing care to
patients with HTLV infection.
III In occupational settings, HTLV-1 transmission is
similar to other blood borne viruses (HIV).
There is insufficient evidence to
recommend occupational postexposure
prophylaxis for those who are exposed to
HTLV-1.
III The use of antiretrovirals immediately after exposure
could theoretically prevent the establishment of
infection, but there are only in vitro data to support
this.
ATL = adult T cell leukemia; HAM/TSP = HTLV-associated myelopathy/tropical spastic paraparesis; HIV = human immunodeficiency virus;
HTLV = human T cell lymphotrophic virus; OPO = organ procurement organizations; PCR = polymerase chain reaction; SOT = solid organ
transplant.
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seropositive donors be used. As routine HTLV-1
screening of deceased donors is no longer performed
by most OPOs, the most likely scenario would be a
living donor in whom confirmatory testing could be
performed or a high risk deceased donor in whom
screening and confirmatory testing is performed
(Category II-3).
(2) Due to the low seroprevalence of HTLV-1 in the
United States and the poor positive predictive value
of screening HTLV-1/2 assays in this population, rou-
tine screening of all deceased donors is not recom-
mended (Category II-3).
(3) Individual OPOs with higher prevalence populations
(e.g. a high proportion of immigrants from en-
demic countries) could consider targeted or universal
screening. However, even in these higher risk donors,
most screen positive donors likely will not have HTLV-I
(Category III).
(4) Living donors with epidemiological risk factors for
HTLV-1 should be screened for HTLV-1 as in this situ-
ation adequate time to perform confirmatory testing
is available (Category III).
(5) Recipients of confirmed or suspected HTLV-1 in-
fected organs should undergo periodic monitoring us-
ing both serological and nucleic acid based testing
(quarterly for 1 year then every 6 months for 1 year)
(Category III).
(6) Follow up of HTLV-positive SOT recipients should in-
clude regular clinical monitoring for complications of
infection, including ATL and HAM/TSP (focusing on
the skin, lymph nodes, hematologic system and neu-
rologic system) (Category III).
(7) SOT recipients who are HTLV-infected (or received po-
tentially infected organs) should be counseled about
risks of transmission to others, including how to
minimize those risks (Category III).
(8) SOT recipients who are at risk for acquiring HTLV-
1 should be counseled on modes of transmission
and how to minimize the risk of acquisition. In gen-
eral, these recommendations follow those for other
viruses such at HIV or hepatitis C (Category III).
(9) Standard, universal precautions should be employed
when providing care to patients with HTLV-1 infection
(Category III).
(10) There is insufficient evidence to recommend occu-
pational postexposure prophylaxis for those who are
exposed to HTLV-1 (Category III).
Future Research
A number of important issues regarding HTLV-1/2 and SOT
recipients remain undefined. Perhaps most importantly,
given the recent elimination of the requirement for de-
ceased donor HTLV-1/2 screening, the transplant commu-
nity should monitor for cases of ATL or HAM in recipients
that could represent donor derived infection. If significant
numbers of cases are noted, targeted donor screening or
universal screening using improved assays could be con-
sidered. We also need to better understand the effect
of immunosuppression on the natural history of asymp-
tomatic HTLV-1 infection, and additional case series from
endemic regions are needed. Finally, further studies are
needed to better define the role of antiretrovirals as post-
exposure prophylaxis.
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